2 results
Approved WMOCompleted
The primary objective of the study is to assess the safety and performance of Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system (Akesys Prava
Approved WMOCompleted
To demonstrate a 25% increase of docetaxel in tumor tissue after intravenous with CriPec® docetaxel compared to Taxotere®. Additionally, systemic PK profile and adverse events will also be evaluated.